Bayer Logo Bayer Logo Bayer Logo Bayer Logo

Welcome to the Bayer
Hemophilia Treatment Hub

Here to help you

Explore our products and resources for advancing hemophilia care

Latest in hemophilia news

Stay up to date with the latest news in hemophilia

NOVEMBER 22, 2018


Bayer receives EU approval for its hemophilia A treatment Jivi®

Read more

SEPTEMBER 21, 2018


Bayer’s Jivi® approved in Japan for hemophilia A

Read more

AUGUST 29, 2018


US approval for hemophilia A treatment Jivi®

Read more

Breaking boundaries

Bayer in hemophilia

Bayer has over 30 years of research and development in hemophilia, exemplified best by our portfolio of recombinant FVIII therapies, which include Kogenate FS/Bayer, Kovaltry, and Jivi.

Besides improving FVIII replacement therapy, Bayer is also pursuing alternative treatment approaches in hemophilia, including gene therapy.

Read more